Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

15 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

C-aryl glucoside derivative, preparation methods thereof, and medical applications thereof

Youngene Therapeutics

Tricyclic heterocyclic compounds useful as inhibitors of TNF

Bristol-Myers Squibb

8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives

Idorsia Pharmaceuticals

Compounds as rearranged during transfection (RET) inhibitors

Glaxosmithkline

Therapeutic compounds and uses thereof

Genentech

Engineering novel specificities for ligand-activated transcription in the nuclear hormone receptor RXR.

University of Texas Southwestern Medical Center

Chemical phylogenetics of histone deacetylases.

Dana-Farber Cancer Institute

Splicing factor SF3b as a target of the antitumor natural product pladienolide.

Eisai

Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy.

Universita Degli Studi Di Milano

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.

Johnson & Johnson Pharmaceutical

Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.

Gsk

Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.

Kochi Medical School

First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.

Nerviano Medical Sciences

Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.

Bristol-Myers Squibb

Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles.

University of Milano